Role of SGLT2 Inhibitors in Type 2 Diabetes Management

Introduction to SGLT2 Inhibitors

SGLT2 inhibitors should be used as a preferred treatment option in type 2 diabetes patients with established cardiovascular disease, heart failure, or chronic kidney disease, regardless of baseline HbA1c levels, due to their proven benefits in reducing cardiovascular events, heart failure hospitalizations, and progression of kidney disease 1, 2

SGLT2 inhibitors work by blocking sodium-glucose cotransporters in the proximal tubule of the kidney, reducing glucose reabsorption and increasing urinary glucose excretion 3
The glucose-lowering effect is more pronounced in hyperglycemic states and diminishes as blood glucose normalizes 3

SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) have demonstrated significant reductions in major adverse cardiovascular events (MACE) in patients with established cardiovascular disease 3, 4
For patients with type 2 diabetes and established atherosclerotic cardiovascular disease, SGLT2 inhibitors are recommended to reduce MACE, heart failure hospitalizations, and cardiovascular death 5
Empagliflozin specifically has shown a 38% reduction in cardiovascular death and a 35% reduction in heart failure hospitalizations in the EMPA-REG OUTCOME trial 3

SGLT2 inhibitors are strongly recommended for patients with heart failure (particularly with reduced ejection fraction) to reduce hospitalizations for heart failure, MACE, and cardiovascular death 6, 2
For patients with or without established atherosclerotic CVD but with heart failure with reduced ejection fraction (HFrEF, EF <45%), SGLT2 inhibitors provide the greatest level of evidence for benefit 6

SGLT2 inhibitors are recommended to prevent progression of chronic kidney disease (CKD), reduce heart failure hospitalizations, MACE, and cardiovascular death in patients with type 2 diabetes and CKD 6, 7
They are particularly beneficial for patients with eGFR 30-60 mL/min/1.73 m² and/or albuminuria (especially UACR >300 mg/g) 6, 2
The glycemic benefits of SGLT2 inhibitors are reduced when eGFR is <45 mL/min/1.73 m² 2

For patients with type 2 diabetes and established cardiovascular disease, heart failure (especially HFrEF), or CKD with albuminuria, SGLT2 inhibitors should be considered regardless of baseline HbA1c 6, 1
For patients without established cardiovascular or kidney disease but with multiple risk factors, SGLT2 inhibitors can be considered as part of the treatment regimen 5
For patients with eGFR <30 mL/min/1.73 m², GLP-1 receptor agonists are preferred over SGLT2 inhibitors for glycemic management 2
For patients with foot ulcers or at high risk for amputation, careful shared decision-making is required before initiating SGLT2 inhibitors 6